サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1666160

子宮内膜症治療の世界市場：2025年～2033年

Global Endometriosis Treatment Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.92円
子宮内膜症治療の世界市場：2025年～2033年
出版日: 2025年02月24日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

子宮内膜症の有病率の上昇は、治療市場の拡大を促す主要因です。子宮内膜症と診断される人が増えるにつれ、効果的な治療オプションに対する需要は増加の一途をたどっています。例えば、2024年の世界保健機関（WHO）によると、子宮内膜症は世界の生殖年齢にある女性と女児の推定10％（1億9,000万人）に影響を及ぼしています。

多くの女性が激しい痛み、不妊症、その他の合併症に直面しており、幅広い症状に対処し、生活の質全体を改善できる治療の必要性が強調されています。同様に、2023年のEuropean Journal of Medical and Health Sciencesの報告によると、子宮内膜症は世界で2億4,700万人、インドでは4,200万人の女性が罹患しているとされています。より良い治療オプションに対するニーズの高まりは、医薬品と外科的ソリューションの両方の技術革新に拍車をかけています。子宮内膜症に対する認識が高まり、より効果的な治療法が登場するにつれて、子宮内膜症治療市場は今後も成長を続けると予想されます。

子宮内膜症の新たな治療法の創出に伴う開発コストの高さが、治療市場の成長を妨げると予想されます。子宮内膜症に対する効果的な治療法の開発には、広範な研究、臨床試験、規制当局の承認が必要であり、これらすべてに費用と時間がかかります。特に子宮内膜症という病気の複雑な性質と普遍的に有効な治療法の開発という課題を考慮すると、この高いコストは新薬や医療機器の開発に投資しようとする製薬会社の数を制限する可能性があります。

当レポートでは、世界の子宮内膜症治療市場について調査し、市場の概要とともに、治療タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法と範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
  • 影響分析

第5章 戦略的洞察と業界の展望

  • 市場のリーダーと先駆者
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第6章 治療タイプ別

  • 鎮痛薬
  • ホルモン療法

第7章 薬剤クラス別

  • NSAID
  • 経口避妊薬
  • ゴナドトロピン放出ホルモン
  • その他

第8章 投与経路別

  • 経口
  • 注射
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • eコマース
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第11章 競合情勢

第12章 企業プロファイル

  • Bayer AG
  • AbbVie, Inc
  • AstraZeneca
  • Gedeon Richter Plc.
  • TORRENT PHARMACEUTICALS LTD.
  • Sanofi SA
  • Gynogen
  • Weefsel Pharma

第13章 付録

目次
Product Code: PH9152

The global Endometriosis Treatment market reached US$ 1.59 billion in 2024 and is expected to reach US$ 3.91 billion by 2033, growing at a CAGR of 10.62% during the forecast period 2025-2033.

Endometriosis is a chronic condition that causes tissue, similar to the lining inside the uterus, to grow outside of it. This tissue commonly develops on the ovaries, fallopian tubes, and the outer walls of the uterus. As the tissue responds to hormonal changes, it can result in severe pain, particularly during menstruation, as well as other symptoms such as pelvic discomfort, pain during sex, heavy bleeding, and infertility.

Treatment for endometriosis focuses on alleviating pain, slowing the growth of the endometrial tissue, and improving fertility if needed. Common approaches include pain relief through nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies like birth control pills, progestins, and GnRH agonists, which help regulate hormone levels and reduce the growth of endometrial tissue. These treatments aim to manage the symptoms and offer relief, though more severe cases may require additional interventions.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Endometriosis

The growing prevalence of endometriosis is a major factor driving the expansion of the treatment market. As more people are diagnosed, the demand for effective treatment options continues to grow. For instance, according to the World Health Organization in 2024, Endometriosis is affecting an estimated 10% (190 million) of women and girls of reproductive age globally

Many women face severe pain, infertility, and other complications, which underscores the need for treatments that can address the wide range of symptoms and improve overall quality of life. Similarly, according to the report by the European Journal of Medical and Health Sciences in 2023, it is stated that endometriosis affects ~247 million women globally and ~42 million women in India. This growing need for better treatment options is spurring innovations in both pharmaceutical and surgical solutions. As awareness increases and more effective treatments emerge, the endometriosis treatment market is expected to keep growing in the coming years.

High developmental costs

The high developmental cost associated with creating new treatments for endometriosis is expected to hinder the growth of the treatment market. Developing effective therapies for endometriosis requires extensive research, clinical trials, and regulatory approvals, all of which are expensive and time-consuming. This high cost can limit the number of pharmaceutical companies willing to invest in the development of new drugs or medical devices, especially given the complex nature of the disease and the challenges in creating universally effective treatments.

Segment Analysis

The global endometriosis treatment market is segmented based on product type, application, end-user, and region.

Drug Class:

NSAIDs segment is expected to dominate the global endometriosis treatment market share

The NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) segment is expected to dominate the endometriosis treatment market. This is because they are frequently the first-line treatment for pain associated with endometriosis due to their ability to inhibit prostaglandin production and alleviate cramps.due to their widespread availability, cost-effectiveness, and effectiveness in managing pain.

Endometriosis commonly causes severe pain, especially during menstruation, and NSAIDs like ibuprofen and naproxen are often used as first-line treatments to provide pain relief. These drugs work by blocking the production of prostaglandins, which reduce inflammation and alleviate pain.

Geographical Analysis

North America is expected to hold a significant position in the global endometriosis treatment market share

North America is expected to hold a significant position in the global endometriosis treatment market due to several key factors. Additionally, there is growing awareness about endometriosis, which is driving higher rates of diagnosis and, consequently, the demand for treatment options. The region also benefits from major pharmaceutical companies developing and commercializing new therapies, ensuring that patients have access to cutting-edge treatments.

Furthermore, the increasing focus on women's health issues and initiatives to improve diagnosis and awareness of endometriosis have contributed to the region's dominant market share. Additionally, the strategic activities of market players, such as introducing new products, contribute to market growth in the region.

Research and innovation of advanced solutions are being rigorously made in the region, contributing to the region's market growth. For instance, in January 2025, Celmatix Therapeutics announced its latest drug program, a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The therapeutic drug candidate, developed using the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery, Baylor College of Medicine (BCM), aims to address a critical unmet need in first-line treatments for a range of women's health indications, starting with endometriosis and potentially extending to Polycystic Ovary Syndrome (PCOS) and ovarian aging.

Competitive Landscape

The major global players in the endometriosis treatment market include Bayer AG, Pfizer, Inc., AbbVie, Inc, AstraZeneca, Gedeon Richter Plc., TORRENT PHARMACEUTICALS LTD., Sanofi SA, Gynogen, and Weefsel Pharma among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Endometriosis Treatment Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Endometriosis
    • 4.1.2. Restraints
      • 4.1.2.1. High Developmental Costs
    • 4.1.3. Opportunity
  • 4.2. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Pain Medication*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Hormone Therapy

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. NSAIDs*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Oral Contraceptives
  • 7.4. Gonadotropin-Releasing Hormone
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Injectable
  • 8.4. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacy
  • 9.4. e-Commerce
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Bayer AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. AbbVie, Inc
  • 12.3. AstraZeneca
  • 12.4. Gedeon Richter Plc.
  • 12.5. TORRENT PHARMACEUTICALS LTD.
  • 12.6. Sanofi SA
  • 12.7. Gynogen
  • 12.8. Weefsel Pharma
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us